Pages that link to "Q36455680"

The following pages link to Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer (Q36455680):

Displaying 35 items.

• In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine (Q24337415) (← links)
• The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer (Q26738703) (← links)
• Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease (Q28534235) (← links)
• Integrative analysis to select cancer candidate biomarkers to targeted validation (Q30278389) (← links)
• Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data (Q31070165) (← links)
• Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling (Q35090742) (← links)
• InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. (Q35637392) (← links)
• Prostasomes as a source of diagnostic biomarkers for prostate cancer (Q36737927) (← links)
• The present and future of prostate cancer urine biomarkers (Q37007392) (← links)
• Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer (Q37060938) (← links)
• Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes (Q37370501) (← links)
• Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression (Q37672628) (← links)
• Novel approaches for the identification of biomarkers of aggressive prostate cancer (Q38117841) (← links)
• Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for protein markers with potential clinical utility (Q38132914) (← links)
• Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer (Q38188878) (← links)
• Seminal plasma as a diagnostic fluid for male reproductive system disorders (Q38202841) (← links)
• Recent progress in urinary proteome analysis for prostate cancer diagnosis and management (Q38613772) (← links)
• Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application (Q38967490) (← links)
• Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. (Q42151262) (← links)
• Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients (Q42775329) (← links)
• Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis (Q46432012) (← links)
• Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer. (Q47100267) (← links)
• Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer (Q47110549) (← links)
• Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives (Q47282493) (← links)
• Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy (Q47660938) (← links)
• Precise quantitation of 136 urinary proteins by LC/MRM-MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies. (Q50991029) (← links)
• Characterization of Protein Content Present in Exosomes Isolated from Conditioned Media and Urine. (Q51021016) (← links)
• Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. (Q55447045) (← links)
• (Q57130729) (← links)
• Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology (Q58695249) (← links)
• The influence of BRCA2 mutation on localized prostate cancer (Q91945235) (← links)
• Search for Novel Diagnostic Biomarkers of Prostate Inflammation-Related Disorders: Role of Transglutaminase Isoforms as Potential Candidates (Q92276539) (← links)
• Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies (Q92564379) (← links)
• Recent advances in mass spectrometry based clinical proteomics: applications to cancer research (Q96134614) (← links)
• PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III (Q102059097) (← links)